The economic impact of chronic obstructive pulmonary disease.

摘要: The cost burden associated with chronic bronchitis and emphysema, collectively known as obstructive pulmonary disease (COPD), is large. impacts not only on patients but caregivers society well. An estimated 16 million people in the US are currently diagnosed COPD, majority having bronchitis. Mortality this upswing, its prevalence female population elderly. It fourth most common cause of death both worldwide. To date, proven cost-effective therapies for cessation or prevention smoking, which single vaccination to prevent influenza pneumococcal infection. Hospitalisation costs represent greatest healthcare expenditures disease. Long-term oxygen therapy also among costly interventions terms total money spent direct medical COPD treatment, although it probably because positive impact rates mortality. In fact, intervention date that has been shown decrease due COPD. Appropriate treatment medication potential resource utilisation does appear affect rates. Similarly, rehabilitation programs benefit quality life; however, long-term cost-effectiveness effects mortality have yet be elucidated. Indirect contribute a substantial part economic significantly harder quantify.